CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of Single-agent Pazopanib (Votrient®) for Patients With Relapsed or Refractory Germ-cell Tumors (GCT).

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01743482
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:10.746771+00:00
Published At: 2021-05-14T00:00:00+00:00
Record Updated At: 2021-05-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Germ Cell Tumors", "Measurable Disease"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-05-14"
protocolSection.identificationModule.nctId: "NCT01743482"
protocolSection.identificationModule.officialTitle: "Phase II Study of Single-agent Pazopanib (Votrient\u00ae) for Patients With Relapsed or Refractory Germ-cell Tumors (GCT)."
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.